![]() |
|
|
Vol. 303, Issue 3, 1291-1300, December 2002
Department of Basic Pharmaceutical Sciences, West Virginia
University, Morgantown, West Virginia (A.Y., R.L.H.); and Department of
Medicinal Chemistry, University of Washington, Seattle, Washington
(B.M.K., A.E.R.)
Polymorphism at the cytochrome P450 2D6 (CYP2D6) locus is one of the
most widely known causes of pharmacogenetic variability in humans. Our
goal is to investigate the intrinsic enzymatic differences that exist
among active CYP2D6 isoforms to test the hypothesis that these
enzymatic differences are substrate-dependent. Active CYP2D6.1, 2, 10, and 17 holo-enzymes were expressed in vitro and purified to a high
degree of homogeneity as confirmed with SDS-polyacrylamide gel
electrophoresis, CO-difference spectroscopy, and mass spectral
analysis. Purified enzyme was reconstituted with lipid and cytochrome
P450 reductase in a 2:1 ratio before kinetic analysis. The
reaction rate for dextromethorphan (DXM) O-demethylation, DXM N-demethylation,
codeine O-demethylation, and fluoxetine
N-demethylation catalyzed by each of the variants was
determined. The CYP2D6.10 enzyme was the most impaired, exhibiting an
estimated enzyme efficiency (as
Vmax/Km) 50-fold
lower for DXM O-demethylation and 100-fold lower for
fluoxetine N-demethylation when compared with CYP2D6.1,
whereas no measurable catalytic activity was observed for this variant
toward codeine. The atypical DXM N-demethylation pathway
catalyzed by this variant decreased only 2-fold in comparison. In the
case of CYPD6.17, estimated clearances for each metabolite were
decreased 6 to 33%. Likewise, the intrinsic clearance of CYP2D6.2
enzyme was consistently decreased for each reaction examined,
indicating that the ultra-rapid metabolizer phenotype sometimes
associated with this genotype is not a function of the underlying amino
acid substitutions. Overall enzyme efficiencies for the metabolism of
each substrate therefore decreased in the order of 2D6.1 > 2D6.2 > 2D6.17 > 2D6.10.
This article has been cited by other articles:
![]() |
H. Shen, M. M. He, H. Liu, S. A. Wrighton, L. Wang, B. Guo, and C. Li Comparative Metabolic Capabilities and Inhibitory Profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17 Drug Metab. Dispos., August 1, 2007; 35(8): 1292 - 1300. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. Yu and R. L. Haining EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF MOUSE CYP2D22 Drug Metab. Dispos., July 1, 2006; 34(7): 1167 - 1174. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Koukouritaki, M. T. Poch, E. T. Cabacungan, D. G. McCarver, and R. N. Hines Discovery of Novel Flavin-Containing Monooxygenase 3 (FMO3) Single Nucleotide Polymorphisms and Functional Analysis of Upstream Haplotype Variants Mol. Pharmacol., August 1, 2005; 68(2): 383 - 392. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Foti and M. B. Fisher IMPACT OF INCUBATION CONDITIONS ON BUFURALOL HUMAN CLEARANCE PREDICTIONS: ENZYME LABILITY AND NONSPECIFIC BINDING Drug Metab. Dispos., March 1, 2004; 32(3): 295 - 304. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Thompson, H. Wojno, E. Greiner, E. L. May, K. C. Rice, and D. E. Selley Activation of G-Proteins by Morphine and Codeine Congeners: Insights to the Relevance of O- and N-Demethylated Metabolites at {micro}- and {delta}-Opioid Receptors J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 547 - 554. [Abstract] [Full Text] [PDF] |
||||